Inspire Medical: Golden Opportunity To Monetize A Fundamentally Mispriced Selloff

Why It Matters

The mispricing creates a rare entry point for investors to acquire a cash‑rich, debt‑free sleep‑apnea device leader at a discount, potentially delivering strong risk‑adjusted returns as coding issues resolve.

Key Takeaways

• Revenue dip stems from temporary CPT coding and CMS disruptions.
• $400 M cash, zero debt gives strong balance‑sheet resilience.
• Trades near 1× EV/sales, indicating undervaluation.
• Cash‑secured put at $25 offers >19% annualized return.

Pulse Analysis

Obstructive sleep apnea affects roughly 22 million Americans, driving demand for innovative therapies beyond CPAP. Inspire Medical Systems dominates the upper airway stimulation (UAS) segment with its FDA‑cleared implant that offers a surgical alternative. The recent revenue contraction is tied to a temporary CPT coding revision and the CMS Project WISeR rollout, both of which have paused reimbursements for new implants. These hurdles are procedural, not reflective of product efficacy, and are expected to clear once coding guidance stabilizes, reopening the growth pipeline for the company.

From a financial perspective, Inspire’s balance sheet is unusually robust for a mid‑size med‑tech firm. With about $400 million in liquidity and zero debt, the company can weather short‑term cash flow swings and fund R&D without dilutive financing. Its current market price translates to roughly 1× enterprise‑value‑to‑sales, a stark discount compared with peers that trade at 3–5× EV/sales. This valuation gap, combined with a high cash runway, positions Inspire as an attractive acquisition target or a platform for organic expansion, especially as GLP‑1 therapies broaden the treatable patient pool.

Investors can monetize the mispricing through a cash‑secured put at a $25 strike, which the author projects will generate more than a 19% annualized return while preserving a 40% downside cushion. The strategy leverages the market’s technical uncertainty, allowing participants to collect premium and potentially acquire shares at a price well below intrinsic value. As coding issues resolve and the UAS market matures, the upside potential could be substantial, making the put structure a compelling risk‑adjusted play for portfolio diversification.